STRASBOURG, France & CROISSY-BEAUBOURG, France, January 13, 2022– (BUSINESS WIRE) – Regulatory news:
THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnosis of autoimmune diseases and theranostics, and BIOSYNEX (ISIN: FR0011005933, Ticker: ALBIO), leader in the Rapid Diagnostic Tests market in France, announces the signing of a distribution agreement.
Following the acquisition of shares on the market and its participation in the capital increase of THERADIAG in November 20211, BIOSYNEX held 2,468,932 shares as of November 29, 2021, representing 18.82% of the capital of THERADIAG2.
In this context, constructive discussions took place between BIOSYNEX management and THERADIAG with the aim of identifying areas for cooperation and improving performance and implementing specific action plans.
As such, a first two-year distribution agreement was signed between THERADIAG and BIOSYNEX for the AMPLIQUICK SARS-CoV-2 PCR test from BIOSYNEX, which will be promoted in hospitals by THERADIAG, which benefits from a strong presence in the environment. hospital, and in particular in the great majority of CHUs.
As an extension of this first contract, BIOSYNEX and THERADIAG intend to explore the possibilities of developing joint projects.
In addition, it is already planned that the Board of Directors of THERADIAG will include a representative of BIOSYNEX whose appointment will be submitted to the vote of the shareholders at the latest at the next General Meeting of THERADIAG.
Theradiag is the market leader in monitoring biotherapies. Capitalizing on its expertise in the diagnostics market, the Company develops, manufactures and markets innovative products in vitro diagnostic tests (IVD) for over 30 years.
Theradiag was the pioneer of “theranostic” tests (combining therapy and diagnosis) which measure the effectiveness of biotherapy in the treatment of chronic inflammatory diseases. Beyond the simple diagnosis, Theranostics aims to help clinicians set up a “personalized treatment” for each patient. This method promotes the individualization of treatment, the evaluation of its effectiveness and the prevention of drug resistance. To respond to this challenge, Theradiag develops and markets the CE marked TRACKER® range, a global solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, is present in more than 70 countries and employs more than 60 people. In 2020, the Company achieved sales of 10.4 million euros. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for PEA-PME.
For more information about Theradiag, please visit our website: https://www.theradiag.com/
Created in 2005 and based in Illkirch-Graffenstaden in Alsace, a major player in public health with more than 200 employees, the French laboratory Biosynex designs, manufactures and distributes Rapid Diagnostic Tests (RDTs). In their professional version, they offer better medical care for patients thanks to the speed of their results and their ease of use. In their self-test version, they allow patients to self-check various pathologies thus ensuring better prevention and accelerating the request for care. Biosynex is the leader in the RTD market in France and is the only player to fully master its value chain thanks to its technological platform, which can be used in various applications and adapted to different types of users such as laboratories, hospitals, doctors. and the general public. More information on www.biosynex.com
1 THERADIAG press release of November 24, 2021
2 BIOSYNEX press release of November 29, 2021.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220112005904/en/
Bertrand de Castelnau
CEO / Managing Director
Phone. : +33 (0) 1 64 62 10 12
Financial Communication & Investor Relations
Phone. : +33 (0) 1 44 71 94 94
Phone. : +33 (0) 1 44 71 94 98
+33 1 44 70 20 84
+ 33 1 80 81 50 00